STAAR SURGICAL CO (STAA): Results of Operations and Financial Condition
STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Reports Second Quarter 2026 Results Net Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA 1 of $20.0 million, or $0.39 per diluted share Earnings Call and We
How this was made
The 30-second read
Why it matters
The filing discloses quarterly financial performance (revenue, net income, gross margin, adjusted EBITDA, and cash) and provides management’s near-term demand and mix outlook, especially for China and EVO+ adoption.
Market read
Traders can update near-term expectations for STAAR based on the magnitude of Y/Y growth, margin level, and the China-driven demand narrative.
What to watch
Management cites no excess distributor or hospital inventory in China, but traders may still scrutinize channel inventory, ASP sustainability, and the impact of the one-time $25.9M order booked in Q3 2025 on year-over-year comparisons.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 reporting STAAR Surgical’s second quarter 2026 results and CEO/CFO commentary.
Ticker impact
STAAR reported Q2 2026 net sales of $93.5M (+111% Y/Y) and net income of $8.1M, plus cash of $181.5M at July 3, 2026.
Near-term bias positive as traders price in accelerating China/EVO+ adoption and improving margin trajectory.
The filing provides concrete quarterly financials (sales, net income, gross margin, EBITDA, cash) and qualitative drivers (EVO+ launch mix, toric lens ASP, no excess inventory), which can move expectations for subsequent quarters.
Market effects
Supports the broader narrative of growth in lens-based refractive surgery and potential share shift versus laser-based procedures in China.
Highlights China as the key growth engine (over 50% of revenue) with sequential improvement and APAC ex-China strength.
Reinforces demand durability for implantable collamer lenses, which may influence sentiment toward ophthalmic medtech peers with China exposure.
Counterpoint
The results may be heavily influenced by China-specific dynamics and mix shifts, so investors should watch whether growth sustains through the typical Q3 seasonal step-down.
Key entities
- issuerSTAAR Surgical Company
Reports Q2 2026 results, including +111% Y/Y net sales, profitability improvement, and cash balance at July 3, 2026.
- product_familyEVO+
Management cites successful EVO+ launch in Q1 2026 as supporting product mix and China growth in Q2.
- executiveDeborah Andrews
Continues as CFO and becomes Executive Vice President, per CEO commentary in the filing.
